During prostate cancer progression, androgen-deprivation therapy is no longer effective, resulting in castration resistant prostate cancer (CRPC) in which the AR signaling is reactivated upon AR gene amplification, mutations, or truncations. This evidence concerns the gene AR and prostate cancer.